According to industry sources, owner successors of leading Korean biotech firms drew significant attention as they stepped forward at the 44th JPMorgan Healthcare Conference held recently in San Francisco.
#JPMorgan #JPMHC #Celltrion #Lotte #SK #bio #it #itchosun #chosun #SouthKorea #Korea
#JPMorgan #JPMHC #Celltrion #Lotte #SK #bio #it #itchosun #chosun #SouthKorea #Korea
Next-Generation Leaders of K-Bio Put to the Test at JPMorgan
As owner heirs of major Korean biotech companies took center stage at the JPMorgan Healthcare Conference (JPMHC)—the world’s largest pharmaceutical and biotech
it.chosun.com
January 20, 2026 at 5:03 AM
There are plenty of ways to fill white space on your #JPMHC24 calendar with this JPMHC Week Guide from MacDougall Advisors and BioCentury. jpmguide.com
January 7, 2024 at 7:06 AM
There are plenty of ways to fill white space on your #JPMHC24 calendar with this JPMHC Week Guide from MacDougall Advisors and BioCentury. jpmguide.com
Fri news: Novo’s new Wegovy pill shows solid launch data. JPMHC takeaways. Legal questions swirl around new FDA priority review program. Sanofi rumored to be bidding to takeover Ocular Therapeutix. Trump’s new healthcare proposal and drugmakers. —https://bit.ly/3JeBlY5
January 16, 2026 at 5:13 PM
Fri news: Novo’s new Wegovy pill shows solid launch data. JPMHC takeaways. Legal questions swirl around new FDA priority review program. Sanofi rumored to be bidding to takeover Ocular Therapeutix. Trump’s new healthcare proposal and drugmakers. —https://bit.ly/3JeBlY5
Thurs news: Boston Sci buying Penumbra for $14.5B. JPMHC: Astellas CEO talks Xtandi patent cliff. Lilly, Sanofi among delayed FDA priority reviews. FDA/EMA collab on AI drug development guidelines. JNJ’s case for earlier Tecvayli multiple myeloma use —https://bit.ly/3JeBlY5
January 15, 2026 at 5:03 PM
Thurs news: Boston Sci buying Penumbra for $14.5B. JPMHC: Astellas CEO talks Xtandi patent cliff. Lilly, Sanofi among delayed FDA priority reviews. FDA/EMA collab on AI drug development guidelines. JNJ’s case for earlier Tecvayli multiple myeloma use —https://bit.ly/3JeBlY5
Wed news: JPMHC: AZ’s $80B revenue target within reach. AbbVie, Amgen, Lilly lead calls for updated post-approval change rules. JPMHC: Biotech IPO sector poised to rebound. Travere hammered on surprise FDA delay. Boston Sci gets new PFA catheter approval. —https://bit.ly/3JeBlY5
January 14, 2026 at 5:12 PM
Wed news: JPMHC: AZ’s $80B revenue target within reach. AbbVie, Amgen, Lilly lead calls for updated post-approval change rules. JPMHC: Biotech IPO sector poised to rebound. Travere hammered on surprise FDA delay. Boston Sci gets new PFA catheter approval. —https://bit.ly/3JeBlY5
Tue news: FDA requests removal of suicide warning from GLP-1s. BMS touts pipeline confidence in core pipeline at JPM. JPMHC: Merck sees growth through Keytruda exclusivity loss. Illumina launches dataset to speed up AI drug discovery. Ro and Amgen to study GLP-1 access. —https://bit.ly/3JeBlY5
January 13, 2026 at 5:11 PM
Tue news: FDA requests removal of suicide warning from GLP-1s. BMS touts pipeline confidence in core pipeline at JPM. JPMHC: Merck sees growth through Keytruda exclusivity loss. Illumina launches dataset to speed up AI drug discovery. Ro and Amgen to study GLP-1 access. —https://bit.ly/3JeBlY5
Mon news: Early signals from our AI survey. Reports that Lilly is preparing a bid for Abivax. JPMHC: AbbVie buys RemeGen cancer drug. Novartis makes $1.5B+ cancer play. Nvidia and Eli Lilly are launching an AI drug discovery lab. —https://bit.ly/3JeBlY5
January 12, 2026 at 5:05 PM
Mon news: Early signals from our AI survey. Reports that Lilly is preparing a bid for Abivax. JPMHC: AbbVie buys RemeGen cancer drug. Novartis makes $1.5B+ cancer play. Nvidia and Eli Lilly are launching an AI drug discovery lab. —https://bit.ly/3JeBlY5
January 12 2026 - Early signals from our AI survey: use is growing, confidence is not January 12 2026 - Early signals from our AI survey: use is growing, confidence is not admin Mon, 01/12/2026 - 1...
Origin | Interest | Match
Origin | Interest | Match
January 12 2026 - Early signals from our AI survey: use is growing, confidence is not | Cafepharma
As JPMHC 2026 gets underway, today’s headlines reflect an industry in motion—marked by dealmaking, investment announcements, and early signals on where confidence is still catching up with adoption.Early signals from our AI survey: use is growing, confidence is notAI surveyEli Lilly reportedly prepares €15bn bid for French biotech AbivaxEli Lilly boardJPM: AbbVie pays $650m upfront for RemeGen cancer drug
www.cafepharma.com
January 12, 2026 at 9:29 PM
January 9 2026 - Why JPM 2026 will mark the end of the healthcare deal drought January 9 2026 - Why JPM 2026 will mark the end of the healthcare deal drought admin Fri, 01/09/2026 - 11:39 With JPMH...
Origin | Interest | Match
Origin | Interest | Match
January 9 2026 - Why JPM 2026 will mark the end of the healthcare deal drought | Cafepharma
With JPMHC set to kick off Monday, today’s headlines point to a thawing deal environment, as M&A; chatter, platform partnerships, and FDA wins build momentum.Why JPM 2026 will mark the end of the healthcare deal droughtPharma/Biotech General Discussion boardNovartis charts next US investment with plan for new radiopharma plant in FloridaNovartis board
www.cafepharma.com
January 9, 2026 at 7:14 PM
Lessons from #JPMHC 2025 must include the opportunity for medical tourism. Patients who cannot get surgery, pharma products, or assistive devices in their own countries will travel to places where they can get such support.
January 18, 2025 at 2:43 AM
Lessons from #JPMHC 2025 must include the opportunity for medical tourism. Patients who cannot get surgery, pharma products, or assistive devices in their own countries will travel to places where they can get such support.
The #JPMHC 2025 in San Francisco is wrapping up today. I sense that public discussion of upcoming regulatory changes was understated. Prepare for changes to longstanding business models in healthcare.
January 17, 2025 at 3:29 AM
The #JPMHC 2025 in San Francisco is wrapping up today. I sense that public discussion of upcoming regulatory changes was understated. Prepare for changes to longstanding business models in healthcare.
2026 엔비디아, 일라이 릴리 동맹으로 보는 제약 산업의 변화
2026년 1월, 샌프란시스코에서 열린 J.P. 모건 헬스케어 컨퍼런스(JPMHC)의 주인공은 신약 파이프라인이 아닌 **'컴퓨팅 인프라'**였습니다. 공식 자료를 더 보고 싶으신 분은 아래에서 확인이 가능합니다. This analysis by goodnotes interprets publicly available data and policy signals from a long-term investment and capital-allocation…
2026년 1월, 샌프란시스코에서 열린 J.P. 모건 헬스케어 컨퍼런스(JPMHC)의 주인공은 신약 파이프라인이 아닌 **'컴퓨팅 인프라'**였습니다. 공식 자료를 더 보고 싶으신 분은 아래에서 확인이 가능합니다. This analysis by goodnotes interprets publicly available data and policy signals from a long-term investment and capital-allocation…
2026 엔비디아, 일라이 릴리 동맹으로 보는 제약 산업의 변화
2026년 1월, 샌프란시스코에서 열린 J.P. 모건 헬스케어 컨퍼런스(JPMHC)의 주인공은 신약 파이프라인이 아닌 **'컴퓨팅 인프라'**였습니다. 공식 자료를 더 보고 싶으신 분은 아래에서 확인이 가능합니다. This analysis by goodnotes interprets publicly available data and policy signals from a long-term investment and capital-allocation perspective. The focus is on structural shifts rather than short-term forecasts. 거시 환경: '실험'에서 '연산'으로의 패러다임 전이 2026년 J.P. 모건 헬스케어 컨퍼런스에서 발표된 **NVIDIA와 일라이 릴리(Eli Lilly)**의 10억 달러 규모 공동 AI 연구소 설립은 제약 산업의 근간을 뒤흔드는 사건입니다. 이는 더 이상 신약 개발이 '운과 우연'에 기대는 물리적 실험의 반복이 아니라, 데이터와 연산 능력이 결정하는 **'생성 생물학(Generative Biology)'**의 영역으로 진입했음을 선포한 것입니다.
bd-notes2155.com
January 13, 2026 at 8:30 AM
2026 엔비디아, 일라이 릴리 동맹으로 보는 제약 산업의 변화
2026년 1월, 샌프란시스코에서 열린 J.P. 모건 헬스케어 컨퍼런스(JPMHC)의 주인공은 신약 파이프라인이 아닌 **'컴퓨팅 인프라'**였습니다. 공식 자료를 더 보고 싶으신 분은 아래에서 확인이 가능합니다. This analysis by goodnotes interprets publicly available data and policy signals from a long-term investment and capital-allocation…
2026년 1월, 샌프란시스코에서 열린 J.P. 모건 헬스케어 컨퍼런스(JPMHC)의 주인공은 신약 파이프라인이 아닌 **'컴퓨팅 인프라'**였습니다. 공식 자료를 더 보고 싶으신 분은 아래에서 확인이 가능합니다. This analysis by goodnotes interprets publicly available data and policy signals from a long-term investment and capital-allocation…
The real value of conferences like JPMHC isn't the official agenda. Commenters agreed that private meetings, networking, and deal-making are the primary drivers for attendance. It's where the actual business happens, away from the spotlight. #Networking 2/6
January 15, 2026 at 8:00 PM
The real value of conferences like JPMHC isn't the official agenda. Commenters agreed that private meetings, networking, and deal-making are the primary drivers for attendance. It's where the actual business happens, away from the spotlight. #Networking 2/6
Overview: Hacker News debated the J.P. Morgan Healthcare Conference. Many questioned its true value, noting a stark contrast between formal talks and crucial informal networking & deal-making happening outside. Comments were often witty and cynical about industry gatherings. #JPMHC 1/6
January 15, 2026 at 8:00 PM
Overview: Hacker News debated the J.P. Morgan Healthcare Conference. Many questioned its true value, noting a stark contrast between formal talks and crucial informal networking & deal-making happening outside. Comments were often witty and cynical about industry gatherings. #JPMHC 1/6
Biswa Sengupta, Jinhua Wang, Leo Brunswic: JPmHC Dynamical Isometry via Orthogonal Hyper-Connections https://arxiv.org/abs/2602.18308 https://arxiv.org/pdf/2602.18308 https://arxiv.org/html/2602.18308
February 23, 2026 at 6:34 AM
Biswa Sengupta, Jinhua Wang, Leo Brunswic: JPmHC Dynamical Isometry via Orthogonal Hyper-Connections https://arxiv.org/abs/2602.18308 https://arxiv.org/pdf/2602.18308 https://arxiv.org/html/2602.18308